Sepsis
causes
millions
of
deaths
per
year
worldwide
and
is
a
current
global
health
priority
declared
by
the
WHO.
Sepsis-related
are
result
dysregulated
inflammatory
immune
responses
indicating
need
to
develop
strategies
target
inflammation.
An
important
mediator
inflammation
extracellular
adenosine
triphosphate
(ATP)
that
released
inflamed
host
cells
tissues,
also
bacteria
in
strain-specific
growth-dependent
manner.
Here,
we
investigated
mechanisms
which
release
ATP.
Using
genetic
mutant
strains
Escherichia
coli
(
E.
),
demonstrate
ATP
dependent
on
synthase
within
inner
bacterial
membrane.
In
addition,
impaired
integrity
outer
membrane
notably
contributes
associated
with
death.
mouse
model
abdominal
sepsis,
local
effects
were
analyzed
using
transformed
bearing
an
arabinose-inducible
periplasmic
apyrase
hydrolyzing
be
released.
Abrogating
shows
suppresses
responses,
resulting
reduced
neutrophil
counts
survival.
has
systemic
via
its
transport
vesicles
(OMV).
ATP-loaded
OMV
quickly
distributed
throughout
body
upregulated
expression
genes
activating
degranulation
neutrophils,
potentially
contributing
exacerbation
sepsis
severity.
This
study
reveals
roles
pathogenesis.
BMC Immunology,
Journal Year:
2025,
Volume and Issue:
26(1)
Published: Jan. 14, 2025
Interleukin-6
(IL-6)
plays
a
central
role
in
sepsis-induced
cytokine
storm
involving
immune
hyperactivation
and
early
neutrophil
activation.
Programmed
death
protein-1
(PD-1)
is
associated
with
immunosuppression
lymphocyte
apoptosis.
However,
the
effects
of
simultaneous
blockade
IL-6
PD-1
murine
sepsis
model
are
not
well
understood.
In
this
study,
was
induced
male
C57BL/6
mice
through
cecal
ligation
puncture
(CLP).
blockade,
or
combination
both
administered
24
h
after
CLP.
Peripheral
blood
count,
level,
apoptosis
spleen,
infiltration
lungs
liver,
survival
rate
were
measured.
The
mortality
IL-6/PD-1
group
lower,
though
statistically
significant
(p
=
0.164),
than
that
CLP
(75.0%
vs.
91.7%).
had
lower
percentage
platelet
count
compared
group;
no
difference
observed
other
levels.
also
showed
reduced
T
spleen
decreased
liver
lungs.
dual
reduces
infiltration,
apoptosis,
bacterial
burden
while
preserving
tissue
integrity
sepsis.
Although
improvement
significant,
these
findings
highlight
its
potential
as
therapeutic
approach
Chronic
inflammation
is
mainly
characterized
by
the
release
of
proinflammatory
cytokines
(cytokine
storm)
and
reactive
oxygen/nitrogen
species.
Sepsis
a
life-threatening
condition
resulting
from
successive
chronic
inflammatory
responses
toward
infection,
leading
to
multiple
organ
failure
and,
ultimately,
death.
As
oxidative
stress
are
known
nourish
each
other
initiate
an
uncontrolled
immune
response,
inhibiting
cross-talk
between
response
using
anti-inflammatory
drugs
antioxidants
can
be
promising
strategy
target
sepsis.
Here,
we
present
engineering
chimeric
nanomicelles
(NMs)
ester-linked
polyethylene
glycol-derived
lithocholic
acid–drug
conjugate
dexamethasone
(DEX),
potent
glucocorticoid
possessing
properties,
vitamin
E
(VITE),
antioxidant
stress.
Interestingly,
these
DEX-VITE
NMs
show
enhanced
accumulation
at
inflamed
sites
driven
permeation
retention
effect
mitigate
localized
acute
in
paw,
lung,
liver
models.
We
further
demonstrated
efficacy
mitigating
LPS-induced
endotoxemia
CLP-induced
microbial
sepsis,
conferring
survival
advantages.
also
modulate
homeostasis
decreasing
infiltration
total
cells,
neutrophils,
overall
macrophages.
Finally,
administration
reduces
prevents
vascular
damage,
two
critical
factors
sepsis
pathogenesis.
Therefore,
this
therapeutic
approach
effectively
deliver
steroids
systemic
inflammation.
Cells,
Journal Year:
2024,
Volume and Issue:
13(14), P. 1172 - 1172
Published: July 9, 2024
Sepsis,
a
condition
characterized
by
life-threatening
organ
dysfunction
due
to
dysregulated
host
response
infection,
significantly
impacts
global
health,
with
mortality
rates
varying
widely
across
regions.
Traditional
therapeutic
strategies
that
target
hyperinflammation
and
immunosuppression
have
largely
failed
improve
outcomes,
underscoring
the
need
for
innovative
approaches.
This
review
examines
development
of
agents
sepsis,
focus
on
clinical
trials
addressing
immunosuppression.
It
highlights
frequent
failures
these
trials,
explores
underlying
reasons,
outlines
current
research
efforts
aimed
at
bridging
gap
between
theoretical
advancements
applications.
Although
personalized
medicine
phenotypic
categorization
present
promising
directions,
this
emphasizes
importance
understanding
complex
pathogenesis
sepsis
developing
targeted,
effective
therapies
enhance
patient
outcomes.
By
multifaceted
nature
future
can
pave
way
more
precise
individualized
treatment
strategies,
ultimately
improving
management
prognosis
patients.
Sepsis
causes
millions
of
deaths
per
year
worldwide
and
is
a
current
global
health
priority
declared
by
the
WHO.
Sepsis-related
are
result
dysregulated
inflammatory
immune
responses
indicating
need
to
develop
strategies
target
inflammation.
An
important
mediator
inflammation
extracellular
adenosine
triphosphate
(ATP)
that
secreted
inflamed
host
cells
tissues,
also
bacteria
in
strain-specific
growth
phase-dependent
manner.
Here,
we
investigated
mechanisms
which
release
ATP.
Using
genetic
mutant
strains
Escherichia
coli
(E.
coli),
demonstrate
ATP
dependent
on
synthase
within
inner
bacterial
membrane.
In
addition,
impaired
integrity
outer
membrane
death
notably
contribute
release.
mouse
model
abdominal
sepsis,
local
effects
were
analysed
using
transformed
E.
bearing
an
arabinose-inducible
periplasmic
apyrase
hydrolyzing
be
released.
Abrogating
shows
suppresses
responses,
resulting
reduced
neutrophil
counts
survival.
has
systemic
via
its
transport
vesicles
(OMV).
ATP-loaded
OMV
quickly
distributed
throughout
body
upregulated
expression
genes
activating
degranulation
neutrophils,
potentially
contributing
exacerbation
sepsis
severity.
This
study
reveals
roles
pathogenesis.
Biomolecules and Biomedicine,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Jan. 7, 2025
Sepsis-induced
myocardial
dysfunction
(SIMD)
is
a
severe
complication
of
sepsis,
characterized
by
impaired
cardiac
function
and
high
mortality
rates.
Despite
significant
advances
in
understanding
sepsis
pathophysiology,
the
molecular
mechanisms
underlying
SIMD
remain
incompletely
elucidated.
Ubiquitination
deubiquitination,
critical
post-translational
modifications
(PTMs)
regulating
protein
stability,
localization,
activity,
play
pivotal
roles
cellular
processes,
such
as
inflammation,
apoptosis,
mitochondrial
function,
calcium
handling.
Dysregulation
these
systems
has
been
increasingly
implicated
pathogenesis
SIMD.
This
review
provides
comprehensive
overview
pathological
driving
SIMD,
with
focus
on
classification
functions
E3
ubiquitin
ligases
deubiquitinating
enzymes
(DUBs),
their
regulatory
systems,
involvement
Dysfunction
ubiquitin-proteasome
system
(UPS),
often
driven
altered
activity
ligases,
accelerates
degradation
proteins,
thereby
exacerbating
oxidative
stress,
apoptosis.
Concurrently,
imbalances
DUB
disrupt
homeostasis,
further
amplifying
injury.
Emerging
research
underscores
therapeutic
potential
targeting
systems.
Strategies
aimed
at
modulating
ligase
or
restoring
balance
have
shown
promise
preclinical
studies.
summarizes
current
findings
ubiquitination
deubiquitination
pathogenesis,
highlights
key
challenges
advancing
this
field,
proposes
directions
for
future
research.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
15
Published: Jan. 8, 2025
Sepsis
is
a
severe
and
life-threatening
medical
syndrome
that
can
lead
to
organ
failure
death.
Despite
advances
in
treatment,
current
therapies
are
often
inadequate,
with
high
septic
mortality
rates.
Therefore,
there
critical
need
for
reliable
prognostic
markers
be
used
clinical
settings
improve
the
management
outcomes
of
patients
sepsis.
Recent
studies
have
suggested
mitochondrial
dynamics,
including
processes
fission
fusion,
closely
related
severity
sepsis
status
inflammation.
By
monitoring
transcriptomic
signals
new
biomarkers
engineered
more
accurately
predict
survival
risk.
Such
would
invaluable
settings,
aiding
healthcare
providers
early
identification
high-risk
improving
treatment
strategies.
To
achieve
this
goal,
we
utilized
major
regulatory
protein
dynamin-related
1
(Drp1,
gene
code
DNM1L)
identified
Drp1-associated
genes
enriched
genes.
A
12-gene
signature
(GS)
was
established
as
differentially
expressed
(DEG)-based
GS.
Next,
compared
proteins
interact
Drp1
7
common
genes,
establishing
GS
term
protein-protein
interaction
(PPI)-based
evaluate
if
these
GSs
survival,
publicly
available
human
blood
datasets
from
patients.
We
confirmed
both
successfully
discovery
validation
cohorts
sensitivity
specificity,
PPI-based
showing
enhanced
performance.
Together,
study
engineers
validated
blood-borne
biomarker
(PPI-based
7-gene
GS)
risk
prediction.
This
holds
potential
optimizing
personalized
strategies
reduce
mortality.
Frontiers in Immunology,
Journal Year:
2025,
Volume and Issue:
16
Published: Jan. 22, 2025
Background
This
study
aimed
to
explore
the
possible
value
of
follicular
helper
T
(Tfh)
cells
in
hospital-acquired
pneumonia
(HAP).
Methods
Flow
cytometry
was
used
measure
circulating
Tfh
and
cell
(Th)
62
HAP
patients
16
healthy
individuals.
were
further
categorized
into
uncontrolled
controlled
groups,
accordance
with
relevant
guidelines.
Subgroup
analyses
additionally
conducted
based
on
pathogen
presence
bloodstream
infections
(BSIs)
incidence
septic
shock.
Kaplan-Meier
survival
analysis
ROC
performed
estimate
prognostic
combination
Tfh/Th
ratios
PCT
levels.
Results
The
ratio
notably
higher
than
controls
(P<0.05).
Specifically,
either
Klebsiella
pneumoniae
(K.p)
-positive
or
BSIs
subgroups
shock
showed
significantly
increased
level
increased.
However,
there
no
significant
differences
between
K.p-infected
non-K.p-infected
patients.
So,
is
a
good
supplement
for
distinguishing
K.p
non-K.p
groups.
also
demonstrated
strong
correlation
procalcitonin
(PCT)
levels
Accordingly,
could
serve
as
more
effective
predictive
marker
deterioration
prediction.
high
along
had
lower
28-day
rate.
Conclusion
ratio,
instrumental
gauging
severity
HAP,
be
employed
biomarker
HAP.